Core Points - A class action lawsuit has been filed against Biohaven Ltd. in the U.S. District Court for the District of Connecticut on behalf of investors who acquired Biohaven securities during the period from March 24, 2023, to May 14, 2025 [1][3] - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1][3] Allegations - The lawsuit claims that Biohaven made false or misleading statements regarding the likelihood of regulatory approval for its drug troriluzole to treat SCA, as well as the strength of the supporting data [4] - Additionally, it is alleged that Biohaven overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder [4]

Core Insights - The J.M. Smucker Company is under investigation for potential violations of federal securities laws and unlawful business practices [1][3] Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3] - For Q3 2025, Smucker reported a comparable net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3] - In Q4 2025, Smucker experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, incurring an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [4] - Following the disappointing Q4 results, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [4] Strategic Outlook - The company updated its 2026 financial plan to reflect decreased net sales in the Sweet Baked Snacks segment, indicating sustained underperformance since the acquisition of Hostess Brands [4]

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure - On July 18, 2025, Barnes & Noble disclosed that there may be an overstatement of up to $23.0 million in its accounts receivable balance as of the fiscal year-end on May 3, 2025, due to issues related to the recording of digital sales costs [3]. - Following this disclosure, Barnes & Noble's share price fell by $2.36, or approximately 21%, closing at $8.87 per share on July 21, 2025 [3]. Legal Context - The investigation by Kirby McInerney LLP focuses on whether Barnes & Noble and/or its officers have engaged in unlawful business practices that could affect shareholders [1][4]. - The law firm specializes in securities litigation and has a history of recovering billions of dollars for shareholders [6].

Core Viewpoint - Replimune Group, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price after receiving a Complete Response Letter from the FDA regarding its lead product RP1 [1][3]. Company Summary - Replimune received a Complete Response Letter from the FDA on July 22, 2025, indicating that its IGNYTE trial was not considered adequate for demonstrating the effectiveness of RP1 in combination with nivolumab for advanced melanoma [3]. - Following the FDA's announcement, Replimune's stock price fell by $9.52, or approximately 77.24%, closing at $2.81 per share [3]. Legal Investigation Summary - Kirby McInerney LLP is investigating potential claims against Replimune and its officers for possible violations of federal securities laws and other unlawful business practices [1][4].

Core Viewpoint - Encompass Health Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following reports of safety concerns at its rehabilitation hospitals [1][3]. Group 1: Investigation Details - Kirby McInerney LLP is investigating claims against Encompass Health and its officers regarding possible violations of federal securities laws [1]. - The investigation was prompted by a New York Times article that highlighted significant safety issues at Encompass Health's hospitals, including high rates of preventable readmissions and serious operational mistakes [3]. Group 2: Financial Impact - Following the news of the investigation and safety concerns, Encompass Health's stock price fell by $12.39, approximately 10.4%, closing at $107.28 per share on July 15, 2025 [4].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Hallador Energy Company regarding possible violations of federal securities laws and unlawful business practices [1]. Group 1: Company Developments - On May 23, 2025, Hallador disclosed the termination of its exclusivity agreement with a datacenter developer for a potential power supply deal [1]. - Hallador stated that discussions for an additional exclusivity period are ongoing, along with non-exclusive discussions with other parties [1]. - Following the announcement, Hallador's share price fell by $1.38, from $18.83 on May 22, 2025, to $17.45 on May 23, 2025 [1]. Group 2: Legal Investigation - The investigation by Kirby McInerney LLP focuses on whether Hallador and/or its officers have engaged in unlawful business practices [1]. - Investors who purchased Hallador securities and have information related to the investigation are encouraged to contact the law firm [2].

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the July 8, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Compass Group Diversified Holdings, LLC (“Compass” or the “Company”) (NYSE:CODI) securities during the period from May 1, 2024, through May 7, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On May 7, 2025, after the market closed, Compass issued an 8-K ...

Core Viewpoint - A federal securities class action has been filed on behalf of investors in Everus Construction Group, Inc. due to undisclosed issues regarding the company's backlog conversion cycle and revenue recognition delays [1][5]. Company Overview - Everus Construction Group, Inc. was formerly known as MDU Construction Services Group, Inc. and operated as a wholly owned subsidiary of CEHI, LLC, which is a subsidiary of MDU Resources [3]. Financial Performance - On February 11, 2025, Everus reported its fourth quarter and full year 2024 financial results, projecting revenue between $3.0 billion and $3.1 billion and EBITDA between $210 million and $225 million for 2025 [4]. - Following the financial results announcement, Everus shares fell by $12.43, approximately 18%, from $68.42 to $55.99 [4]. Class Action Details - The class action is focused on the period from October 31, 2024, to February 11, 2025, and includes investors who held MDU Resources common stock as of October 21, 2024, and acquired Everus common stock during the spinoff [1]. - The complaint alleges that the company failed to disclose the elongation of its backlog conversion cycle and the resulting delays in revenue recognition [5].

Core Points - A class action lawsuit has been filed against Digimarc Corporation for securities fraud, affecting investors who purchased shares between May 3, 2024, and February 26, 2025 [3][5] - The lawsuit alleges that Digimarc failed to disclose critical information regarding a significant commercial partner's contract renewal, which negatively impacted the company's revenue [5] Financial Performance - For Q4 2024, Digimarc reported a 10% decline in quarterly subscription revenue, falling to $5.0 million from $5.6 million year-over-year [4] - Annual recurring revenue decreased to $20.0 million from $22.23 million in the previous year, primarily due to a $5.8 million drop in ARR linked to the expiration of a commercial contract in June 2024 [4] - Following the financial announcement, Digimarc's share price plummeted by $11.65, approximately 43%, closing at $15.39 on February 27, 2025 [4]

Core Viewpoint - A federal securities class action has been filed against Actinium Pharmaceuticals, with a deadline for investors to seek lead plaintiff status by May 27, 2025, related to securities acquired between October 31, 2022, and August 2, 2024 [1]. Group 1: Company Developments - On August 5, 2024, Actinium announced a regulatory update regarding its Biologics License Application (BLA) for lomab-B, revealing that the FDA required an additional clinical study to support the BLA filing [3]. - Following the announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2024 [3]. Group 2: Legal Allegations - The complaint alleges that during the Class Period, Actinium misled the market regarding the likelihood of its BLA data meeting FDA guidelines for acceptance and approval [4].